EU Clears Cepheid Thrombophilia Tests | GenomeWeb
NEW YORK (GenomeWeb News) – Cepheid today said that European Union regulatory authorities have cleared the firm’s Xpert HemosIL FII & FV assay for marketing.
 
The assay detects Factor II and Factor V Leiden genetic variations associated with thrombophilia. The test was developed for use on Cepheid’s GeneXpert multiplex molecular diagnostics system.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.